Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery

A double blind, randomized clinical trial of efficacy and safety

Ji Ho Kim, Jae Kwang Shim, Jong Wook Song, Young Song, Hye Bin Kim, Younglan Kwak

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Introduction: Recombinant human erythropoietin (EPO) is known to provide organ protection against ischemia-reperfusion injury through its pleiotropic properties. The aim of this single-site, randomized, case-controlled, and double-blind study was to investigate the effect of pre-emptive EPO administration on the incidence of postoperative acute kidney injury (AKI) in patients with risk factors for AKI undergoing complex valvular heart surgery. Methods: We studied ninety-eight patients with preoperative risk factors for AKI. The patients were randomly allocated to either the EPO group (n = 49) or the control group (n = 49). The EPO group received 300 IU/kg of EPO intravenously after anesthetic induction. The control group received an equivalent volume of normal saline. AKI was defined as an increase in serum creatinine >0.3 mg/dl or >50% from baseline. Biomarkers of renal injury were serially measured until five days postoperatively. Results: Patient characteristics and operative data, including the duration of cardiopulmonary bypass, were similar between the two groups. Incidence of postoperative AKI (32.7% versus 34.7%, P = 0.831) and biomarkers of renal injury including cystatin C and neutrophil gelatinase-associated lipocalin showed no significant differences between the groups. The postoperative increase in interleukin-6 and myeloperoxidase was similar between the groups. None of the patients developed adverse complications related to EPO administration, including thromboembolic events, throughout the study period. Conclusions: Intravenous administration of 300 IU/kg of EPO did not provide renal protection in patients who are at increased risk of developing AKI after undergoing complex valvular heart surgery.Trial registration: Clinical Trial.gov, NCT01758861.

Original languageEnglish
Article numberR254
JournalCritical Care
Volume17
Issue number5
DOIs
Publication statusPublished - 2013 Oct 24

Fingerprint

Erythropoietin
Acute Kidney Injury
Thoracic Surgery
Randomized Controlled Trials
Safety
Incidence
Kidney
Biomarkers
Cystatin C
Control Groups
Wounds and Injuries
Reperfusion Injury
Cardiopulmonary Bypass
Double-Blind Method
Intravenous Administration
Peroxidase
Anesthetics
Interleukin-6
Creatinine
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Critical Care and Intensive Care Medicine

Cite this

@article{8ebe866815524c1db8007e757e8669b7,
title = "Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: A double blind, randomized clinical trial of efficacy and safety",
abstract = "Introduction: Recombinant human erythropoietin (EPO) is known to provide organ protection against ischemia-reperfusion injury through its pleiotropic properties. The aim of this single-site, randomized, case-controlled, and double-blind study was to investigate the effect of pre-emptive EPO administration on the incidence of postoperative acute kidney injury (AKI) in patients with risk factors for AKI undergoing complex valvular heart surgery. Methods: We studied ninety-eight patients with preoperative risk factors for AKI. The patients were randomly allocated to either the EPO group (n = 49) or the control group (n = 49). The EPO group received 300 IU/kg of EPO intravenously after anesthetic induction. The control group received an equivalent volume of normal saline. AKI was defined as an increase in serum creatinine >0.3 mg/dl or >50{\%} from baseline. Biomarkers of renal injury were serially measured until five days postoperatively. Results: Patient characteristics and operative data, including the duration of cardiopulmonary bypass, were similar between the two groups. Incidence of postoperative AKI (32.7{\%} versus 34.7{\%}, P = 0.831) and biomarkers of renal injury including cystatin C and neutrophil gelatinase-associated lipocalin showed no significant differences between the groups. The postoperative increase in interleukin-6 and myeloperoxidase was similar between the groups. None of the patients developed adverse complications related to EPO administration, including thromboembolic events, throughout the study period. Conclusions: Intravenous administration of 300 IU/kg of EPO did not provide renal protection in patients who are at increased risk of developing AKI after undergoing complex valvular heart surgery.Trial registration: Clinical Trial.gov, NCT01758861.",
author = "Kim, {Ji Ho} and Shim, {Jae Kwang} and Song, {Jong Wook} and Young Song and Kim, {Hye Bin} and Younglan Kwak",
year = "2013",
month = "10",
day = "24",
doi = "10.1186/cc13081",
language = "English",
volume = "17",
journal = "Critical Care",
issn = "1466-609X",
publisher = "BioMed Central Ltd.",
number = "5",

}

Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery : A double blind, randomized clinical trial of efficacy and safety. / Kim, Ji Ho; Shim, Jae Kwang; Song, Jong Wook; Song, Young; Kim, Hye Bin; Kwak, Younglan.

In: Critical Care, Vol. 17, No. 5, R254, 24.10.2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery

T2 - A double blind, randomized clinical trial of efficacy and safety

AU - Kim, Ji Ho

AU - Shim, Jae Kwang

AU - Song, Jong Wook

AU - Song, Young

AU - Kim, Hye Bin

AU - Kwak, Younglan

PY - 2013/10/24

Y1 - 2013/10/24

N2 - Introduction: Recombinant human erythropoietin (EPO) is known to provide organ protection against ischemia-reperfusion injury through its pleiotropic properties. The aim of this single-site, randomized, case-controlled, and double-blind study was to investigate the effect of pre-emptive EPO administration on the incidence of postoperative acute kidney injury (AKI) in patients with risk factors for AKI undergoing complex valvular heart surgery. Methods: We studied ninety-eight patients with preoperative risk factors for AKI. The patients were randomly allocated to either the EPO group (n = 49) or the control group (n = 49). The EPO group received 300 IU/kg of EPO intravenously after anesthetic induction. The control group received an equivalent volume of normal saline. AKI was defined as an increase in serum creatinine >0.3 mg/dl or >50% from baseline. Biomarkers of renal injury were serially measured until five days postoperatively. Results: Patient characteristics and operative data, including the duration of cardiopulmonary bypass, were similar between the two groups. Incidence of postoperative AKI (32.7% versus 34.7%, P = 0.831) and biomarkers of renal injury including cystatin C and neutrophil gelatinase-associated lipocalin showed no significant differences between the groups. The postoperative increase in interleukin-6 and myeloperoxidase was similar between the groups. None of the patients developed adverse complications related to EPO administration, including thromboembolic events, throughout the study period. Conclusions: Intravenous administration of 300 IU/kg of EPO did not provide renal protection in patients who are at increased risk of developing AKI after undergoing complex valvular heart surgery.Trial registration: Clinical Trial.gov, NCT01758861.

AB - Introduction: Recombinant human erythropoietin (EPO) is known to provide organ protection against ischemia-reperfusion injury through its pleiotropic properties. The aim of this single-site, randomized, case-controlled, and double-blind study was to investigate the effect of pre-emptive EPO administration on the incidence of postoperative acute kidney injury (AKI) in patients with risk factors for AKI undergoing complex valvular heart surgery. Methods: We studied ninety-eight patients with preoperative risk factors for AKI. The patients were randomly allocated to either the EPO group (n = 49) or the control group (n = 49). The EPO group received 300 IU/kg of EPO intravenously after anesthetic induction. The control group received an equivalent volume of normal saline. AKI was defined as an increase in serum creatinine >0.3 mg/dl or >50% from baseline. Biomarkers of renal injury were serially measured until five days postoperatively. Results: Patient characteristics and operative data, including the duration of cardiopulmonary bypass, were similar between the two groups. Incidence of postoperative AKI (32.7% versus 34.7%, P = 0.831) and biomarkers of renal injury including cystatin C and neutrophil gelatinase-associated lipocalin showed no significant differences between the groups. The postoperative increase in interleukin-6 and myeloperoxidase was similar between the groups. None of the patients developed adverse complications related to EPO administration, including thromboembolic events, throughout the study period. Conclusions: Intravenous administration of 300 IU/kg of EPO did not provide renal protection in patients who are at increased risk of developing AKI after undergoing complex valvular heart surgery.Trial registration: Clinical Trial.gov, NCT01758861.

UR - http://www.scopus.com/inward/record.url?scp=84886744969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886744969&partnerID=8YFLogxK

U2 - 10.1186/cc13081

DO - 10.1186/cc13081

M3 - Article

VL - 17

JO - Critical Care

JF - Critical Care

SN - 1466-609X

IS - 5

M1 - R254

ER -